理邦儀器(300206.SZ):2019年淨利預增25%-50%
格隆匯1月17日丨理邦儀器(300206.SZ)披露2019年年度業績預告,公司預計2019年1-12月實現歸屬於上市公司股東的淨利潤1.16億元-1.39億元,同比增長25%-50%。業績變動原因説明:
1、報告期內,公司加大國內外市場的開拓力度,持續挖掘各細分市場潛力,加上新興產品持續發力,營業收入保持穩定增長,本期營業利潤較上年同期大幅增加;其中婦幼產品和體外診斷產品線及子公司智慧健康增長趨勢良好。
2、公司全面實施精細化管理,挖潛增效,進一步提升管理和運營效率,促進毛利率的提升,同時也強化成本費用控制。
3、報告期公司非經常性損益對淨利潤影響預計為1400萬元左右,主要為政府補助和理財收益。本期政府補助較上年同期減少2560萬元左右。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.